A phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancer

被引:73
作者
Park, YH [1 ]
Ryoo, BY [1 ]
Choi, SJ [1 ]
Kim, HT [1 ]
机构
[1] Korea Inst Radiol & Med Sci, Dept Internal Med, Div Haematol & Oncol, Seoul 139706, South Korea
关键词
capecitabine; docetaxel; advanced gastric cancer;
D O I
10.1038/sj.bjc.6601724
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Capecitabine and docetaxel have considerable single-agent activity in gastric cancer with distinct mechanisms of action and no overlap of key toxicities. A synergistic interaction between these two drugs is mediated by taxane-induced upregulation of thymidine phosphorylase. We investigated the activity and the feasibility of capecitabine and docetaxel combination chemotherapy in patients with previously untreated advanced gastric cancer (AGC). From September 2001 to March 2003, 42 patients with AGC received 21-day cycles of oral capecitabine (1250 mg m(-2) twice daily on days 1-14) and docetaxel (75 mg m(-2) i.v. on day 1). The patients received a total of 164 cycles of chemotherapy. The median age was 53.5 years (range 33-73 years). The overall response rate in the 38 efficacy-evaluable patients was 60% (95% confidence interval, 45-74%). The median progression-free survival was 5.2 months (range, 1.0-15 + months) and the median overall survival was 10.5 months (range, 2.9-23.7 + months). The most common grade 3/4 adverse events were hand-foot syndrome (HFS: G3 50%), neutropenia (15%) and leucopenia (12%). Further studies of this combination are clearly warranted, albeit with lower doses of both agents (1000 mg m(-2) twice daily and 60 mg m(-2)) to reduce the rate of HFS and onycholysis.
引用
收藏
页码:1329 / 1333
页数:5
相关论文
共 29 条
  • [1] Docetaxel 75 mg/m2 is active and well tolerated in patients with metastatic or recurrent gastric cancer:: a phase II trial
    Bang, YJ
    Kang, WK
    Kang, YK
    Kim, HC
    Jacques, C
    Zuber, E
    Daglish, B
    Boudraa, Y
    Kim, WS
    Heo, DS
    Kim, NK
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2002, 32 (07) : 248 - 254
  • [2] First-line oral capecitabine therapy in metastatic colorectal cancer:: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin
    Cassidy, J
    Twelves, C
    Van Cutsem, E
    Hoff, P
    Bajetta, E
    Boyer, M
    Bugat, R
    Burger, U
    Garin, A
    Graeven, U
    McKendrick, J
    Maroun, J
    Marshall, J
    Osterwalder, B
    Pérez-Manga, G
    Rosso, R
    Rougier, P
    Schilsky, RL
    [J]. ANNALS OF ONCOLOGY, 2002, 13 (04) : 566 - 575
  • [3] Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for advanced gastric carcinoma
    Cho, EK
    Lee, WK
    Lim, DY
    Bang, SM
    Park, DK
    Park, YH
    Kwon, OS
    Choi, DJ
    Shin, DB
    Lee, JH
    Lee, TH
    [J]. JOURNAL OF KOREAN MEDICAL SCIENCE, 2002, 17 (03) : 348 - 352
  • [4] Docetaxel, 5-fluorouracil, and leucovorin as treatment for advanced gastric cancer: Results of a phase II study
    Constenla M.
    Garcia-Arroyo R.
    Lorenzo I.
    Carrete N.
    Campos B.
    Palacios P.
    [J]. Gastric Cancer, 2002, 5 (3) : 142 - 147
  • [5] Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: The eastern cooperative oncology group (ECOG) results of protocol E1293
    Einzig, AI
    Neuberg, D
    Remick, SC
    Karp, DD
    ODwyer, PJ
    Stewart, JA
    Benson, AB
    [J]. MEDICAL ONCOLOGY, 1996, 13 (02): : 87 - 93
  • [6] Docetaxel in advanced gastric cancer
    Haller, DG
    Misset, JL
    [J]. ANTI-CANCER DRUGS, 2002, 13 (05) : 451 - 460
  • [7] Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study
    Hoff, PM
    Ansari, R
    Batist, G
    Cox, J
    Kocha, W
    Kuperminc, M
    Maroun, J
    Walde, D
    Weaver, C
    Harrison, E
    Burger, HU
    Osterwalder, B
    Wang, AO
    Wong, R
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (08) : 2282 - 2292
  • [8] HONG YS, 2002, P AM SOC CLIN ONCOL, V21
  • [9] Jeen YT, 2001, CANCER-AM CANCER SOC, V91, P2288
  • [10] KANG YK, 2003, P AN M AM SOC CLIN, V22, P328